121 related articles for article (PubMed ID: 3591456)
1. Improved survival in multiple myeloma with renal failure.
Wahlin A; Löfvenberg E; Holm J
Acta Med Scand; 1987; 221(2):205-9. PubMed ID: 3591456
[TBL] [Abstract][Full Text] [Related]
2. Improved survival in multiple myeloma with combination chemotherapy and plasmapheresis.
Wahlin A; Holm J; Nyström L
Haematologia (Budap); 1984; 17(4):465-71. PubMed ID: 6532916
[TBL] [Abstract][Full Text] [Related]
3. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy.
Johnson WJ; Kyle RA; Pineda AA; O'Brien PC; Holley KE
Arch Intern Med; 1990 Apr; 150(4):863-9. PubMed ID: 2183734
[TBL] [Abstract][Full Text] [Related]
4. [Acute and chronic renal failure in patients with myeloma].
Biriukova LS; Volodiaeva EB; Fetisova EV; Pivnik AV; Margolin OV
Ter Arkh; 1999; 71(7):58-64. PubMed ID: 10481869
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
6. Management of renal complications in patients with advanced multiple myeloma.
Viertel A; Weidmann E; Ditting T; Geiger H
Leuk Lymphoma; 2000 Aug; 38(5-6):513-9. PubMed ID: 10953972
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis.
Yu X; Gan L; Wang Z; Dong B; Chen X
Int J Clin Pharmacol Ther; 2015 May; 53(5):391-7. PubMed ID: 25816886
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
9. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
Gola A; Usnarska-Zubkiewicz L; Wołowiec D; Urbaniak-Kujda D; Kotlarek-Haus S
Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946
[TBL] [Abstract][Full Text] [Related]
10. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.
Carlson K; Hjorth M; Knudsen LM;
Br J Haematol; 2005 Mar; 128(5):631-5. PubMed ID: 15725084
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
12. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
Bladé J; San Miguel JF; Fontanillas M; Alcalá A; Maldonado J; García-Conde J; Conde E; Conzález-Brito G; Moro MJ; Escudero ML; Trujillo J; Pascual A; Rozman C; Estapé J; Montserrat E
J Clin Oncol; 1996 Jul; 14(7):2167-73. PubMed ID: 8683251
[TBL] [Abstract][Full Text] [Related]
13. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Case DC; Lee DJ; Clarkson BD
Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
[No Abstract] [Full Text] [Related]
14. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
[TBL] [Abstract][Full Text] [Related]
15. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
[TBL] [Abstract][Full Text] [Related]
16. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
17. Management of myeloma kidney: an anti-light-chain approach.
Misiani R; Tiraboschi G; Mingardi G; Mecca G
Am J Kidney Dis; 1987 Jul; 10(1):28-33. PubMed ID: 3111253
[TBL] [Abstract][Full Text] [Related]
18. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
19. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
20. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
Raab MS; Breitkreutz I; Hundemer M; Benner A; Klaus J; Hegenbart U; Moehler T; Ho AD; Zeier M; Goldschmidt H
Haematologica; 2006 Nov; 91(11):1555-8. PubMed ID: 17082013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]